The FDA doesn't publish a pen testing checklist, but its guidance, 524B requirements, and reviewer expectations add up to one. Here's what medical device makers must cover before, during, and after the test.

R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Section 524B made medical device cybersecurity a legal requirement, not a guideline. Learn what the FDA expects from your pen test scope, evidence package, and postmarket vulnerability management process.

Semiconductor manufacturers face dual compliance obligations under CMMC 2.0 and the CHIPS Act and a standard pen test satisfies neither fully. Learn how to build a unified program that covers both frameworks.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.